Plummer-Vinson syndrome secondary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
Patients of Plummer-Vinson syndrome are at a risk (10-15%) of developing malignant lesions (squamous cell carcinoma) of the oral mucosa, hypopharynx and esophagus. Effective measures for the secondary prevention of Plummer-Vinson syndrome include an upper gastrointestinal endoscopy every year to rule out malignant changes.
Patients of Plummer-Vinson syndrome are at a risk (10-15%) of developing [[malignant]] lesions ([[squamous cell carcinoma]]) of the [[oral mucosa]], [[hypopharynx]] and [[esophagus]]. Effective measures for the [[secondary prevention]] of Plummer-Vinson syndrome include an upper [[Gastrointestinal tract|gastrointestinal]] [[endoscopy]] every year to rule out [[malignant]] transformation.


==Secondary Prevention==
==Secondary Prevention==
Patients of Plummer-Vinson syndrome are at a risk (10-15%) of developing malignant lesions (squamous cell carcinoma) of the oral mucosa, hypopharynx and esophagus. Effective measures for the secondary prevention of Plummer-Vinson syndrome include:
Patients of Plummer-Vinson syndrome are at a risk (10-15%) of developing [[malignant]] lesions ([[squamous cell carcinoma]]) of the [[oral mucosa]], [[hypopharynx]] and [[esophagus]]. Effective measures for the [[secondary prevention]] of Plummer-Vinson syndrome include:
*Upper gastrointestinal endoscopy every year
*Upper gastrointestinal [[endoscopy]] every year


==References==
==References==

Revision as of 18:29, 1 November 2017

Plummer-Vinson syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Plummer-Vinson syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Plummer-Vinson syndrome secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Plummer-Vinson syndrome secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Plummer-Vinson syndrome secondary prevention

CDC on Plummer-Vinson syndrome secondary prevention

Plummer-Vinson syndrome secondary prevention in the news

Blogs on Plummer-Vinson syndrome secondary prevention

Directions to Hospitals Treating Plummer-Vinson syndrome

Risk calculators and risk factors for Plummer-Vinson syndrome secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Akshun Kalia M.B.B.S.[2]

Overview

Patients of Plummer-Vinson syndrome are at a risk (10-15%) of developing malignant lesions (squamous cell carcinoma) of the oral mucosa, hypopharynx and esophagus. Effective measures for the secondary prevention of Plummer-Vinson syndrome include an upper gastrointestinal endoscopy every year to rule out malignant transformation.

Secondary Prevention

Patients of Plummer-Vinson syndrome are at a risk (10-15%) of developing malignant lesions (squamous cell carcinoma) of the oral mucosa, hypopharynx and esophagus. Effective measures for the secondary prevention of Plummer-Vinson syndrome include:

References